Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

SWATH-MS Proteomic Analysis of Oxygen-Induced Retinopathy Reveals Novel Potential Therapeutic Targets.

Vähätupa M, Nättinen J, Jylhä A, Aapola U, Kataja M, Kööbi P, Järvinen TAH, Uusitalo H, Uusitalo-Järvinen H.

Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3294-3306. doi: 10.1167/iovs.18-23831.

PMID:
30025079
2.

Generation of a multi-functional, target organ-specific, anti-fibrotic molecule by molecular engineering of the extracellular matrix protein, decorin.

Järvinen TAH, Ruoslahti E.

Br J Pharmacol. 2018 May 30. doi: 10.1111/bph.14374. [Epub ahead of print] Review.

PMID:
29847688
3.

Rescue plan for Achilles: Therapeutics steering the fate and functions of stem cells in tendon wound healing.

Schneider M, Angele P, Järvinen TAH, Docheva D.

Adv Drug Deliv Rev. 2018 Apr;129:352-375. doi: 10.1016/j.addr.2017.12.016. Epub 2017 Dec 24. Review.

4.

Recombinant Decorin Fusion Protein Attenuates Murine Abdominal Aortic Aneurysm Formation and Rupture.

Shen Y, Russo V, Zeglinski MR, Sellers SL, Wu Z, Oram C, Santacruz S, Merkulova Y, Turner C, Tauh K, Zhao H, Bozin T, Bohunek L, Zeng H, Seidman MA, Bleackley RC, McManus BM, Ruoslahti E, Järvinen TAH, Granville DJ.

Sci Rep. 2017 Nov 20;7(1):15857. doi: 10.1038/s41598-017-16194-8.

5.

Furin deficiency in myeloid cells leads to attenuated revascularization in a mouse-model of oxygen-induced retinopathy.

Vähätupa M, Cordova ZM, Barker H, Aittomäki S, Uusitalo H, Järvinen TAH, Pesu M, Uusitalo-Järvinen H.

Exp Eye Res. 2018 Jan;166:160-167. doi: 10.1016/j.exer.2017.10.013. Epub 2017 Oct 13.

6.

Arthroscopic partial meniscectomy versus placebo surgery for a degenerative meniscus tear: a 2-year follow-up of the randomised controlled trial.

Sihvonen R, Paavola M, Malmivaara A, Itälä A, Joukainen A, Nurmi H, Kalske J, Ikonen A, Järvelä T, Järvinen TAH, Kanto K, Karhunen J, Knifsund J, Kröger H, Kääriäinen T, Lehtinen J, Nyrhinen J, Paloneva J, Päiväniemi O, Raivio M, Sahlman J, Sarvilinna R, Tukiainen S, Välimäki VV, Äärimaa V, Toivonen P, Järvinen TLN; FIDELITY (Finnish Degenerative Meniscal Lesion Study) Investigators.

Ann Rheum Dis. 2018 Feb;77(2):188-195. doi: 10.1136/annrheumdis-2017-211172. Epub 2017 May 18.

7.

R-Ras deficiency does not affect papain-induced IgE production in mice.

Kummola L, Ortutay Z, Vähätupa M, Prince S, Uusitalo-Järvinen H, Järvinen TAH, Junttila IS.

Immun Inflamm Dis. 2017 Sep;5(3):280-288. doi: 10.1002/iid3.168. Epub 2017 May 11.

8.

Postinjury Exercise and Platelet-Rich Plasma Therapies Improve Skeletal Muscle Healing in Rats But Are Not Synergistic When Combined.

Contreras-Muñoz P, Torrella JR, Serres X, Rizo-Roca D, De la Varga M, Viscor G, Martínez-Ibáñez V, Peiró JL, Järvinen TAH, Rodas G, Marotta M.

Am J Sports Med. 2017 Jul;45(9):2131-2141. doi: 10.1177/0363546517702864. Epub 2017 Apr 28.

PMID:
28453295
9.

Lack of R-Ras Leads to Increased Vascular Permeability in Ischemic Retinopathy.

Vähätupa M, Prince S, Vataja S, Mertimo T, Kataja M, Kinnunen K, Marjomäki V, Uusitalo H, Komatsu M, Järvinen TA, Uusitalo-Järvinen H.

Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4898-4909. doi: 10.1167/iovs.16-19212.

10.

Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition.

Järvinen TA, Prince S.

Biomed Res Int. 2015;2015:654765. doi: 10.1155/2015/654765. Epub 2015 Nov 30. Review.

11.

Systemically Administered, Target Organ-Specific Therapies for Regenerative Medicine.

Järvinen TA, May U, Prince S.

Int J Mol Sci. 2015 Sep 30;16(10):23556-71. doi: 10.3390/ijms161023556. Review.

12.

Resistance of R-Ras knockout mice to skin tumour induction.

May U, Prince S, Vähätupa M, Laitinen AM, Nieminen K, Uusitalo-Järvinen H, Järvinen TA.

Sci Rep. 2015 Jul 2;5:11663. doi: 10.1038/srep11663.

13.

Targeted Antiscarring Therapy for Tissue Injuries.

Järvinen TA, Ruoslahti E.

Adv Wound Care (New Rochelle). 2013 Mar;2(2):50-54. Review.

14.

Correction: Deep Vascular Imaging in Wounds by Two-Photon Fluorescence Microscopy.

Yanez CO, Morales AR, Yue X, Urakami T, Komatsu M, Järvinen TAH, Belfield KD.

PLoS One. 2014 Jan 22;9(1). doi: 10.1371/annotation/59bcbe81-eddd-46a4-90dc-88c1ea70df72. eCollection 2014.

15.

A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.

Toba M, Alzoubi A, O'Neill K, Abe K, Urakami T, Komatsu M, Alvarez D, Järvinen TA, Mann D, Ruoslahti E, McMurtry IF, Oka M.

Am J Pathol. 2014 Feb;184(2):369-75. doi: 10.1016/j.ajpath.2013.10.008. Epub 2014 Jan 6.

16.

Deep vascular imaging in wounds by two-photon fluorescence microscopy.

Yanez CO, Morales AR, Yue X, Urakami T, Komatsu M, Järvinen TA, Belfield KD.

PLoS One. 2013 Jul 2;8(7):e67559. doi: 10.1371/journal.pone.0067559. Print 2013. Erratum in: PLoS One. 2014 Jan 22;9(1):null.

17.

Design of target-seeking antifibrotic compounds.

Järvinen TA.

Methods Enzymol. 2012;509:243-61. doi: 10.1016/B978-0-12-391858-1.00013-7.

PMID:
22568909
18.

Peptide-directed highly selective targeting of pulmonary arterial hypertension.

Urakami T, Järvinen TA, Toba M, Sawada J, Ambalavanan N, Mann D, McMurtry I, Oka M, Ruoslahti E, Komatsu M.

Am J Pathol. 2011 Jun;178(6):2489-95. doi: 10.1016/j.ajpath.2011.02.032. Epub 2011 May 6.

19.

Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice.

Järvinen TA, Ruoslahti E.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21671-6. doi: 10.1073/pnas.1016233107. Epub 2010 Nov 24.

20.

Molecular changes in the vasculature of injured tissues.

Järvinen TA, Ruoslahti E.

Am J Pathol. 2007 Aug;171(2):702-11. Epub 2007 Jun 28.

Supplemental Content

Loading ...
Support Center